Table 4.
Effect of MPNs on work and productivity among respondents who were employed
| Effect on Work/Productivity,a n/Nb (%) | MF (n = 207) | PV (n = 380) | ET (n = 226) |
|---|---|---|---|
| Reduced work hoursc | 70/119 (59) | 91/246 (37) | 50/169 (30) |
| Days sick from workd | |||
| 1–3 | 11/52 (21) | 19/127 (15) | 18/88 (20) |
| 4–6 | 3/52 (6) | 4/127 (3) | 2/88 (2) |
| 7–9 | 0 | 0 | 0 |
| ≥10 | 1/52 (2) | 1/127 (1) | 0 |
| Voluntarily terminated jobc | 39/125 (31) | 54/254 (21) | 19/169 (11) |
| Involuntarily terminated jobc | 6/120 (5) | 11/242 (5) | 7/168 (4) |
| Medical disabilityc | 38/134 (28) | 37/253 (15) | 12/177 (7) |
| Early retirementc | 38/125 (30) | 54/253 (21) | 24/169 (14) |
ET = essential thrombocythemia; MF = myelofibrosis; MPN = myeloproliferative neoplasm; PV = polycythemia vera
aRespondents employed full- or part-time only
bN is the number of respondents who reported “yes” or “no,” excluding those who answered “not applicable.”
cEver
dIn the preceding 30 days